Mustang Bio, Inc. and Minaris Regenerative Medicine GmbH have announced they have signed an agreement to enable technology transfer and GMP clinical manufacturing of MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in Europe.
Minaris Regenerative Medicine announced today a total 64.5 million USD to significantly expand its facilities in Europe and Asia.
The regenerative medicine business of Hitachi Chemical Co., Ltd. announces that it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.
